Keywords
- Apple Juice
- Blood Phenylalanine
- Sapropterin Dihydrochloride
- Blood Phenylalanine Concentration
- ADHD Inattentive Symptom
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Blau N. Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias. Expert Opin Drug Metab Toxicol. 2013;9(9):1207–18.
Kure S, et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr. 1999;135(3):375–8.
BioMarin Pharmaceuticals Inc.. Kuvan [sapropterin dihydrochloride] Tables and powder prescribing information. Novato; 2014.
Levy HL, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet. 2007;370(9586):504–10.
Lee P, et al. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet A. 2008;146A(22):2851–9.
Trefz FK, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr. 2009;154(5):700–7.
Burton BK, et al. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study. Mol Genet Metab. 2011;103(4):315–22.
Musson DG, et al. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults. Clin Ther. 2010;32(2):338–46.
Vockley J, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188–200.
Singh RH, et al. Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. Genet Med. 2014;16(2):121–31.
Cunningham A, et al. Recommendations for the use of sapropterin in phenylketonuria. Mol Genet Metab. 2012;106(3):269–76.
Longo L. et al. Long-term developmental progression in infants and young children taking sapropterin for phenylketonuria: a two-year analysis of safety and efficacy. Gen in Med. 2014. doi:10.1038/gim.2014.109 (in press).
Leuret O, et al. Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria. J Inherit Metab Dis. 2012;35(6):975–81.
Couce ML, et al. Long-term pharmacological management of phenylketonuria, including patients below the age of 4 years. JIMD Rep. 2012;2:91–6.
Burton BK, et al. Tetrahydrobiopterin therapy for phenylketonuria in infants and young children. J Pediatr. 2011;158(3):410–5.
Gassió R, et al. Cognitive functions in patients with phenylketonuria in long-term treatment with tetrahydrobiopterin. Mol Genet Metab. 2010;99 Suppl 1:S75–8.
White DA, et al. White matter integrity and executive abilities following treatment with tetrahydrobiopterin (BH4) in individuals with phenylketonuria. Mol Genet Metab. 2013;110(3):213–7.
Christ SE, et al. The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria. Neuroimage Clin. 2013;3:539–47.
Burton B, et al. A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria. Mol Genet Metab. 2014. http://dx.doi.org/10.1016/j.ymgme.2014.11.011.
Humphrey M, et al. Effect of tetrahydrobiopterin on Phe/Tyr ratios and variation in Phe levels in tetrahydrobiopterin responsive PKU patients. Mol Genet Metab. 2011;104(1–2):89–92.
Singh RH, et al. BH(4) therapy impacts the nutrition status and intake in children with phenylketonuria: 2-year follow-up. J Inherit Metab Dis. 2010;33(6):689–95.
Aldámiz-Echevarría L, et al. Tetrahydrobiopterin therapy vs phenylalanine-restricted diet: impact on growth in PKU. Mol Genet Metab. 2013;109(4):331–8.
Keil S, et al. Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study. Pediatrics. 2013;131(6):e1881–8.
Demirdas S, et al. Evaluation of quality of life in PKU before and after introducing tetrahydrobiopterin (BH4); a prospective multi-center cohort study. Mol Genet Metab. 2013;110(Suppl):S49–56.
Douglas TD, et al. Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride. Health Qual Life Outcomes. 2013;11:218.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Jurecki, E. (2015). Tetrahydrobiopterin Therapy for Phenylketonuria. In: Bernstein, L., Rohr, F., Helm, J. (eds) Nutrition Management of Inherited Metabolic Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-14621-8_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-14621-8_12
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-14620-1
Online ISBN: 978-3-319-14621-8
eBook Packages: MedicineMedicine (R0)